Chemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

DISEASE CHARACTERISTICS:

* Diagnosis of 1 of the following:

  * CD20-positive aggressive B-cell non-Hodgkin's lymphoma (NHL), including any of the following subtypes:

    * Diffuse large cell lymphoma\*, meeting 1 of the following criteria:

      * Relapsed disease after initial therapy, but failed to mobilize or had bone marrow involvement and therefore is not suitable for an autologous stem cell transplantation
      * High-intermediate- or high-risk second-line, age-adjusted International Prognostic Index score and in second complete remission (CR) or partial remission (PR) after autologous stem cell transplantation
      * Failed prior autologous stem cell transplantation and in PR or better after salvage chemotherapy
    * Large cell transformation of indolent NHL or chronic lymphocytic leukemia (CLL), meeting the following criteria:

      * In CR or PR of the large cell component of disease after salvage chemotherapy or autologous stem cell transplantation
    * Mantle cell lymphoma\*, meeting 1 of the following criteria:

      * High-risk disease (e.g., p53 positivity) and in first CR or PR after initial therapy
      * Relapsed disease after initial therapy and in second or third CR or PR after salvage chemotherapy NOTE: \*No progressive disease at allograft work-up
  * CD20-positive indolent NHL (e.g., follicular lymphoma, small cell lymphoma, or marginal zone NHL) OR CLL

    * Second or subsequent progression (pre-allograft cytoreduction necessary, but CR or PR not required)
* Relapsed disease must be biopsy-proven
* Must have received pre-allograft salvage chemotherapy, including 1 of the following:

  * Single autologous stem cell transplantation using high-dose chemotherapy conditioning within the past 120 days
  * At least 2 courses of intensive combination chemotherapy (e.g., RICE \[rituximab, ifosfamide, carboplatin, etoposide\]), according to diagnosis, within the past 80 days
  * CLL patients who have received CAMPATH do not have to receive pre-allograft salvage chemotherapy
* HLA-compatible related or unrelated donor available

  * HLA-matched ≥ 9/10 of the A, B, C, DRB1, and DQB1 loci, as tested by high resolution typing

    * One allele mismatch allowed

PATIENT CHARACTERISTICS:

* Karnofsky performance status 70-100%
* Creatinine \< 1.2 mg/mL OR creatinine clearance ≥ 50 mL/min
* Bilirubin \< 2.5 mg/dL
* AST and ALT ≤ 3 times upper limit of normal (unless benign congenital hyperbilirubinemia is present)
* Spirometry and corrected DLCO ≥ 50% of normal
* LVEF ≥ 40%
* Albumin ≥ 2.5 g/dL
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* No active uncontrolled infection, including active infection with Aspergillus or other mold
* No HIV infection
* No hepatitis B antibody or antigen positivity

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
* No prior allogeneic transplantation